Bladder Cancer

Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract July 17, 2026

Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. July 17, 2026

Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression. July 16, 2026

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study. July 15, 2026

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract July 14, 2026

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract July 14, 2026

Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy. July 14, 2026

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study. July 13, 2026

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility July 10, 2026

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. July 10, 2026

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update. July 17, 2026

Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes. July 17, 2026

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer. July 16, 2026

Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances. July 15, 2026

Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract July 14, 2026

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). July 14, 2026

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study. July 14, 2026

Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer. July 13, 2026

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. July 10, 2026

Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study. July 10, 2026

Page 1 of 607